Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results.

Elion R, Molina JM, Ramón Arribas López J, Cooper D, Maggiolo F, Wilkins E, Conway B, Liu YP, Margot N, Rhee M, Chuck SL, Szwarcberg J; Study 145 Team.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):494-7. doi: 10.1097/QAI.0b013e318298469c.

PMID:
23807156
2.

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL; Study 145 Team.

Lancet Infect Dis. 2012 Jan;12(1):27-35. doi: 10.1016/S1473-3099(11)70249-3. Epub 2011 Oct 18.

PMID:
22015077

Supplemental Content

Loading ...
Support Center